Skip to main content

Table 2 Association between statin use after diagnosis and breast cancer-specific and all-cause mortality in patients with breast cancer

From: Statin use and breast cancer survival: a nationwide cohort study in Scotland

  Breast cancer mortality Patients Person years Age-adjusted HR (95 % CI) P Adjusteda HR (95 % CI) P
[n = 15,140] [n = 13,060]
Breast cancer mortality
 Statin non-user 855 10,907 30,852 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Statin user 335 4,233 10,421 0.87 (0.76,0.99) 0.04 0.95 (0.79,1.15) 0.62
 1-12 prescriptions 201 1,358 5,713 0.91 (ref. cat.) 0.22 0.94 (0.75,1.18) 0.61
 ≥12 prescriptions 134 2,875 4,708 0.82 (0.68,0.99) 0.04 0.97 (0.75,1.25) 0.79
 Simvastatin non-user 966 12,115 33,845 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Simvastatin user 224 3,025 7,428 0.82 (0.71,0.95) 0.01 0.89 (0.73,1.08) 0.24
 Lipophilic non-user 964 12,110 33,836 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Lipophilic user 226 3,030 7,437 0.83 (0.72,0.96) 0.01 0.90 (0.74,1.11) 0.33
 Hydrophilic non-user 1,062 13,434 37,389 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Hydrophilic user 128 1,706 3,884 0.95 (0.79,1.14) 0.57 0.97 (0.76,1.24) 0.82
All-cause mortality
 Statin non-user 1,323 10,907 30,852 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Statin user 684 4,233 10,421 0.95 (0.86,1.04) 0.27 0.88 (0.76,1.01) 0.07
 1–12 prescriptions 365 1,358 5,713 0.92 (0.82,1.04) 0.20 0.86 (0.73,1.02) 0.08
 ≥12 prescriptions 319 2,875 4,708 0.98 (0.86,1.11) 0.74 0.90 (0.75,1.08) 0.27
 Simvastatin non-user 1,527 12,115 33,845 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Simvastatin user 480 3,025 7,428 0.93 (0.84,1.04) 0.21 0.87 (0.75,1.00) 0.06
 Lipophilic non-user 1,525 12,110 33,836 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Lipophilic user 482 3,030 7,437 0.94 (0.85,1.04) 0.23 0.87 (0.75,1.01) 0.072
 Hydrophilic non-user 1,764 13,434 37,389 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Hydrophilic user 243 1706 3884 0.94 (0.83,1.08) 0.41 0.93 (0.77,1.11) 0.40
  1. aModel contains age, year of diagnosis, socioeconomic status, stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular disaese, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease), hormone replacement therapy use (in year prior to diagnosis), and other prescription medication use (tamoxifen, aromatase inhibitor and low-dose aspirin and metformin, as time varying covariates)